hematological malignancies- chronic leukemias

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/49

encourage image

There's no tags or description

Looks like no tags are added yet.

50 Terms

1
New cards

treatment goal for chronic vs acute leukemias

chronic: not treating for cure

acute: curative intent

2
New cards

upregulated myeloid proliferation leading to excess mature neutrophil production

chronic myeloid leukemia

3
New cards

oncogenic protein resulting in the pathogenesis of CML

philadelphia chromosome

4
New cards

what makes up the philadelphia chromosome

BCR-ABL fusion gene on chromosomes 9 and 22

5
New cards

medical emergency presentation of CML

leukocytosis, WBCs as high as 1,000,000 cells

6
New cards

other presentations of CML

fatigue, sweating, bone pain, weight loss, splenomegaly

7
New cards

diagnosis of CML

bone marrow biopsy and CBC

8
New cards

what is monitored during CML treatment

PCR- polymerase chain reaction

9
New cards

phases of CML

Chronic phase, accelerated phase, and blast crisis

10
New cards

CML phase with progressive myeloid maturation, 10-19% blasts

accelerated phase

11
New cards

terminal phase of CML that clinically resembles acute leukemia

blast crisis

12
New cards

goal of CML treatment

eradicate leukemic clone with minimal toxicity

13
New cards

main drug class used in CML

tyrosine kinase inhibitors (TKIs)

14
New cards

molecular response goal of CML

major (MMR): BCR-ABL <0.1%

15
New cards

ideal molecular response for CML

deep: BCR-ABL <0.01%

16
New cards

first generation TKI

imatinib

17
New cards

how does neutropenia caused by imatinib progress after several years

high during years 1-2 then greatly decreases

18
New cards

2nd generation TKIs

Dasatinib

Nilotinib

Bosutinib

19
New cards

3rd generation TKIs

Ponatinib

20
New cards

4th generation TKIs

asciminib

21
New cards

which TKI must be taken BID

nilotinib

22
New cards

main SE of imatinib

nausea

23
New cards

main SE of dasatinib

fluid retention (pleural effusion)

24
New cards

SEs of nilotinib

QTc interval prolongation

metabolic syndrome

25
New cards

SE's: ponatinib (most toxic agent)

ischemic reactions

vascular occlusion

HTN

26
New cards

SEs of asciminib

musculoskeletal pain

dyslipidemia

27
New cards

signs of relapse from CML

any sign of loss of CCyR or an increase in BCR:ABL transcript to >1%

28
New cards

point mutation in CML that leads to resistance to 1st + 2nd generation TKIs

T315I

29
New cards

what can be used to treat CML with T315I mutation

ponatinib, asciminib, omacetaxine

30
New cards

how to treat accelerated phase CML

higher dose of TKI or new TKI to return to chronic phase

31
New cards

how to treat blast phase CML

treat like acute leukemia + TKI

32
New cards

leukemia with mature B lymphocyte accumulation that do not function properly

chronic lymphoid leukemia (CLL)

33
New cards

main patient demographic for CLL

old white men

34
New cards

presentation of CLL

recurrent infections, lymphadenopathy, hepatosplenomegaly, anemia, thrombocytopenia

35
New cards

how to diagnose CLL and what is the diagnostic criteria

diagnosed off of peripheral blood, monoclonal B lymphocytes >5x10^9/L in peripheral blood

36
New cards

what FISH variables lead to an unfavorable risk in CLL

Del(17p) and Del(11q)

37
New cards

what DNA sequencing variables lead to an unfavorable risk in CLL

TP53 mutated and IGHV <2% mutation

38
New cards

who is treated in CLL

stage III/IV, symptomatic, organ dysfunction

39
New cards

first line treatment option for CLL

BTK inhibitors alone or with chemoimmunotherapy

40
New cards

BTK inhibitor based regimens for CLL

acalabrutinib (continuous) + obinutuzumab OR

zanubrutinib (continuous)

41
New cards

BCL2 inhibitor containing regimens for CLL and duration

venetoclax/ acalabrutinib OR

venetoclax + obinutuzumab

finite duration (1 year)

42
New cards

difference in CLL treatment if pt has del(17p)/TP53 mutation

venetoclax/acalabrutinib + obinutuzumab

43
New cards

clinically significant ADE difference between zanubrutinib and ibrutinib

ibrutinib has higher afib risk

44
New cards

take home message of zanubrutinib vs ibrutinib

zanubrutinib has better response with less toxicity

45
New cards

very significant risk of venetoclax

TLS due to apoptosis of cancer cells

46
New cards

pro-apoptotic proteins released by venetoclax

BIM and PUMA

47
New cards

what interactions are significant with venetoclax use

CYP3A4 and Pgp

48
New cards

how to treat relapse or refractory CLL

switch to alternative regimen

CAR-T after BTK inhibitors and BCL2 inhibitor therapy used

49
New cards

toxicities of acalabrutinib + zanubrutinib

HTN, increased risk of hemorrhage, afib

50
New cards

what peaks early in treatment course with BTK inhibitors but does not signify disease progression

lymphocytosis or tumor flare